JP2024028989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024028989A5 JP2024028989A5 JP2023211350A JP2023211350A JP2024028989A5 JP 2024028989 A5 JP2024028989 A5 JP 2024028989A5 JP 2023211350 A JP2023211350 A JP 2023211350A JP 2023211350 A JP2023211350 A JP 2023211350A JP 2024028989 A5 JP2024028989 A5 JP 2024028989A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cooh
- conh
- nhc
- represents hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841001438 | 2018-01-12 | ||
| IN201841001438 | 2018-01-12 | ||
| PCT/IB2019/050219 WO2019138367A1 (en) | 2018-01-12 | 2019-01-11 | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
| JP2020538785A JP7438955B2 (ja) | 2018-01-12 | 2019-01-11 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538785A Division JP7438955B2 (ja) | 2018-01-12 | 2019-01-11 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024028989A JP2024028989A (ja) | 2024-03-05 |
| JP2024028989A5 true JP2024028989A5 (enExample) | 2024-05-16 |
| JP7698699B2 JP7698699B2 (ja) | 2025-06-25 |
Family
ID=67213573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538785A Active JP7438955B2 (ja) | 2018-01-12 | 2019-01-11 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
| JP2023211350A Active JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538785A Active JP7438955B2 (ja) | 2018-01-12 | 2019-01-11 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11274123B2 (enExample) |
| EP (1) | EP3737401A4 (enExample) |
| JP (2) | JP7438955B2 (enExample) |
| KR (2) | KR102800305B1 (enExample) |
| CN (1) | CN111601801A (enExample) |
| AU (2) | AU2019206438B2 (enExample) |
| BR (1) | BR112020014202A2 (enExample) |
| CA (1) | CA3087841A1 (enExample) |
| CU (1) | CU24643B1 (enExample) |
| EA (1) | EA202091267A1 (enExample) |
| IL (1) | IL275952B1 (enExample) |
| MX (1) | MX2020007383A (enExample) |
| MY (1) | MY200800A (enExample) |
| PH (1) | PH12020551062A1 (enExample) |
| SG (1) | SG11202005992XA (enExample) |
| WO (1) | WO2019138367A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091267A1 (ru) * | 2018-01-12 | 2020-11-03 | Ориджен Дискавери Текнолоджис Лимитед | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 |
| WO2020095256A1 (en) * | 2018-11-08 | 2020-05-14 | Aurigene Discovery Technologies Limited | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR102690136B1 (ko) * | 2021-06-30 | 2024-07-31 | 연세대학교 산학협력단 | 바이러스 및 박테리아의 중복 감염 치료용 조성물 |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024545193A (ja) | 2021-12-22 | 2024-12-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025083628A1 (en) | 2023-10-19 | 2025-04-24 | Aurigene Oncology Limited | Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025229631A2 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER |
| WO2025229629A1 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | Combination therapy using a cd47-sirp-alpha blocking agent and azacitidine |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| EP1999119A2 (en) * | 2006-02-15 | 2008-12-10 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| ES2616010T3 (es) | 2010-05-14 | 2017-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anticuerpos monoclonales humanizados y quiméricos a CD47 |
| EA030155B1 (ru) * | 2013-09-06 | 2018-06-29 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,2,4-оксадиазола в качестве иммуномодуляторов |
| ITTO20130731A1 (it) | 2013-09-09 | 2015-03-10 | Indesit Co Spa | Muffola di un forno nella quale sono fissate delle guide |
| KR102708045B1 (ko) * | 2015-03-10 | 2024-09-23 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| BR112017019306A2 (pt) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores |
| CN107427476A (zh) * | 2015-03-10 | 2017-12-01 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| EP3353209B1 (en) | 2015-09-21 | 2022-03-16 | Erasmus University Medical Center Rotterdam | Anti-cd47 antibodies and methods of use |
| JP2019505579A (ja) * | 2015-12-23 | 2019-02-28 | ムーンショット ファーマ エルエルシー | 免疫応答を誘導するための方法 |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| ES2908729T3 (es) | 2016-05-10 | 2022-05-03 | Inst Nat Sante Rech Med | Nuevos compuestos y uso farmacéutico de los mismos en el tratamiento del cáncer |
| EA202091267A1 (ru) * | 2018-01-12 | 2020-11-03 | Ориджен Дискавери Текнолоджис Лимитед | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 |
| WO2020095256A1 (en) * | 2018-11-08 | 2020-05-14 | Aurigene Discovery Technologies Limited | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
-
2019
- 2019-01-11 EA EA202091267A patent/EA202091267A1/ru unknown
- 2019-01-11 JP JP2020538785A patent/JP7438955B2/ja active Active
- 2019-01-11 IL IL275952A patent/IL275952B1/en unknown
- 2019-01-11 WO PCT/IB2019/050219 patent/WO2019138367A1/en not_active Ceased
- 2019-01-11 CU CU2020000046A patent/CU24643B1/es unknown
- 2019-01-11 EP EP19738566.9A patent/EP3737401A4/en active Pending
- 2019-01-11 BR BR112020014202-6A patent/BR112020014202A2/pt unknown
- 2019-01-11 KR KR1020207020398A patent/KR102800305B1/ko active Active
- 2019-01-11 SG SG11202005992XA patent/SG11202005992XA/en unknown
- 2019-01-11 AU AU2019206438A patent/AU2019206438B2/en active Active
- 2019-01-11 CA CA3087841A patent/CA3087841A1/en active Pending
- 2019-01-11 MY MYPI2020003578A patent/MY200800A/en unknown
- 2019-01-11 US US16/245,860 patent/US11274123B2/en active Active
- 2019-01-11 KR KR1020257013071A patent/KR20250057146A/ko active Pending
- 2019-01-11 CN CN201980007859.6A patent/CN111601801A/zh active Pending
- 2019-01-11 MX MX2020007383A patent/MX2020007383A/es unknown
-
2020
- 2020-07-10 PH PH12020551062A patent/PH12020551062A1/en unknown
-
2021
- 2021-01-22 US US17/155,242 patent/US11560403B2/en active Active
-
2023
- 2023-01-05 US US18/150,246 patent/US20230144653A1/en active Pending
- 2023-12-14 JP JP2023211350A patent/JP7698699B2/ja active Active
-
2024
- 2024-03-04 AU AU2024201411A patent/AU2024201411A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024028989A5 (enExample) | ||
| IL275952B1 (en) | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signaling Pathways | |
| JPWO2019138367A5 (enExample) | ||
| HRP20200703T1 (hr) | Derivati 1,2,4-oksadiazola kao imunomodulatori | |
| JP2013150606A5 (enExample) | ||
| RU2490258C2 (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
| JP2008544755A5 (enExample) | ||
| CN104211768B (zh) | β‑咔啉‑3‑羧酸与寡肽的缀合物，其制备，纳米结构和作为抗肿瘤剂的应用 | |
| JPWO2022016070A5 (enExample) | ||
| JP2009155338A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2011514913A5 (enExample) | ||
| JP2003522167A (ja) | 抗腫瘍剤としてのｃ７エステル置換タキサン | |
| JP2011084586A (ja) | ポリアミンおよび治療におけるそれらの使用 | |
| KR20060032994A (ko) | 컨주게이트된 보체 캐스캐이드 억제제 | |
| JP2020507589A5 (enExample) | ||
| JP7618445B2 (ja) | ３－置換１，２，４－オキサジアゾールの結晶形態 | |
| JP2004531543A5 (enExample) | ||
| JP2013199483A (ja) | ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 | |
| HRP20110654T1 (hr) | Dimeri derivata artemizinina, njihovo dobivanje i upotreba u terapiji | |
| CN111171026A (zh) | 含氮化合物或其盐的制造中间体 | |
| JP2007532560A5 (enExample) | ||
| JP2018197268A (ja) | マルトール第二鉄の結晶形態 | |
| JP2013506004A5 (enExample) | ||
| US20130197034A1 (en) | Salts Of Methyl 2-((R)-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3-((R)-Tetrahydro-2H-Pyran-3-Yl)Propylcarbamoyl)Piperidin-3-Yl)Methoxy)Ethylcarbamate |